TheScreener - MLP Saglik Hizmetleri AS (MPARK) MLP SAGLIK HIZMETLERI sees an upgrade to Positive due to a better fundamental star rating

Report

TheScreener

EUR 12.80 For Business Accounts Only

MLP SAGLIK HIZMETLERI sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of MLP SAGLIK HIZMETLERI (TR), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date December 24, 2021, the closing price was TRY 31.82 and its potential was estimated at TRY 38.25.

25/12/2021 6 EN

Underlying

MLP Saglik Hizmetleri AS

MLP Saglik Hizmetleri AS, formerly Medical Park Saglik Hizmetleri AS, is a Turkey-based company engaged in the healthcare sector. The Company operates more than 20 hospitals in more than 10 provinces in Turkey. The Company's medical departments include: Mouth and Dental Health, Brain and Nerve Surgery, Biochemistry, Dermatology, Child Health and Diseases, Physical Therapy and Rehabilitation, Hematology, Check-up, Eye Health and Diseases, Gastroenterology, Cardiac Surgery, Ear-Nose-Throat, Cardiology, Gynecology and Obstetrics, as well as Laboratory Services, among others. The Company's subsidiaries are: Medical Park Gaziantep Hastanesi, Samsun Medikal Grup Ozel Saglik Hizmetleri AS and Sentez Saglik Hizmetleri AS, among others.

See profile

TREMLPC00021 Istanbul Stock Exchange Turkey

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

Ünlü&Co

MLP Care

MLP Care has successfully optimized its hospital portfolio over the past five years by divesting low-margin facilities, integrating high-performing hospitals, and restructuring operations. These factors have strengthened operational efficiency per hospital and per bed since 2022. Additionally, through effective cash flow management and a strategic shift away from FX-denominated debt, MLP Care has lowered its net debt/EBITDA ratio from 2.7x in 2019 to 0.4x in 9M24. While the company has not yet distributed dividends, its buyback and cancellation of 17m shares (8.2% stake) in Oct’24 was a positi...

EUR 58.54

February 18, 2025 February 18, 2025 1 EN

Ünlü&Co

MLP Care

MLP Care has effectively restructured its hospital portfolio over the past four years and implemented cost optimization measures, resulting in a 10% EBITDA CAGR in USD terms from 2019 to 2023. As private health insurance and foreign medical tourism revenues continued to recover, the proportion of revenue exposed to the social security system decreased to 14% by 2023. Concurrently, net debt decreased from USD348m in 2019 to USD110m in 2023, with 70% attributed to lease liabilities. Anticipating a 5% USD based EBITDA CAGR between 2023 and 2025, we project MLP Care to achieve a net cash position ...

EUR 58.54

April 18, 2024 April 18, 2024 1 EN

Ünlü&Co

Model Portfolio Update

Including Turkiye Sigorta and MLP Care to our model portfolio, while removing Alarko Holding: We are including Turkiye Sigorta and MLP Care to our model portfolio while removing Alarko Holding. Turkiye Sigorta: Turkiye Sigorta is a beneficiary from the rise in deposit rates. The company has TL21bn AUM as of Mar’23 and 41% of this was TL bank deposits. On the other hand, FX long position (excl. technical reserves) was TL3.4bn (USD176m) in 1Q23 and we estimate the company to book a significant FX gain in 2Q. With the help of strong financial income, we forecast TL1.5bn net profit in 2Q23, (+162...

EUR 58.54

July 17, 2023 July 17, 2023 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MLP SAGLIK HIZMETLERI sees an upgrade to Positive due to a better fundamental star rating

Empowering Investors

MLP Care

MLP Care

Model Portfolio Update

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe